

参考文献

- Brown D, Wang R, Underwood M, et al. DTG vs LPV/R (DAWNING): Efficacy by Baseline NRTI Resistance and Second-line NRTI Use. CROI 2018. CROI 2019. Abstract 144.
- Bunupuradah T, Chetchotisakd P, Ananworanich J, et al. A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: The HIV STAR study. *Antivir Ther.* 2012;17:1351-1361.
- Castagna A, Maggiolo F, Penco G, et al. Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. *J Infect Dis.* 2014;210: 354-362.
- Cohen CJ, Hunt S, Sension M, et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. *AIDS.* 2002;16:579-588.
- Daar E, DeJesus E, Ruane P, et al. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 weeks results of a randomised, open-label, multicentre, phase 3, non-inferiority trial. *Lancet HIV.* 2018 Jul;5(7):e347-e356.
- Deeks SG, Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. *N Engl J Med.* 2001;344(7):472-480.
- DeJesus, et al. Superior Efficacy and Improved Renal and Bone Safety After Switching From a Tenofovir Disoproxil Fumarate- To a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment. *AIDS Res Hum Retroviruses.* 2018 Apr;34(4):337-342.
- DeJesus, et al. Switching From Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Coformulated With Rilpivirine and Emtricitabine in Virally Suppressed Adults With HIV-1 Infection: A Randomised, Double-Blind, Multicentre, Phase 3b, Non-Inferiority Study. *Lancet HIV.* 2017 May;4(5):e205-e213.
- Derrick C, Ostermann J, Weissmann SB, et al. Who wants to switch? Gauging interest in potential new antiretroviral therapies. *Open Forum Infect Dis.* 2018 Oct 22;5(10):ofy247.